Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia.

ABSTRACT:

Background/aims

Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients.

Methods

We retrospectively analyzed 47 patients diagnosed with WM between 2000 and 2018 to explore risk factors predicting poor prognosis using various clinical and laboratory parameters and risk models including the International Prognostic Staging System for WM (IPSS-WM).

Results

Over a median follow-up duration of 80.4 months, 29 patients died. The main causes of death were disease progression, organ failure related to amyloidosis, and infection. The median overall survival (OS) was

SUBMITTER: Cho JH 

PROVIDER: S-EPMC8137404 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature